To treat or not to treat is still a question

This morning I read a very interesting “food for thought” article, just published in the “Oncology Times,” about the same old same old (question)…that is, should patients with so-called “high risk” smoldering myeloma be treated…or not? Here’s the link (you can download the entire article; look on the right, under “Article Tools”): http://goo.gl/MzG6mj hamlet-duplex-mankoff

I decided to publish the link without adding any comments, since, duh, you can imagine which approach I would choose…no mystery there. And my position in this matter is merely reinforced (in MY opinion, of course) by Dr. Berenson’s comments on the Spanish “high-risk” SMM chemo trial…for example, the “significant design problems” of that trial…hah, no kidding!

I thought it was noteworthy that Dr. Berenson mentions “curcumin” on page 25. Curcumin, as we well know, has  been totally ignored/dismissed/ridiculed/etc. by our specialists and only recently has managed to catch their attention…probably since so many of us take it…

Boy, sometimes it feels as though I’m beating my head against a brick wall…mamma mia.

Incidentally, I was surprised by the audience’s choice, in the end. Very surprised. Or was I, deep down? Hmmm…not sure. Oops, I promised NOT TO COMMENT. Drat. Okay, I will shut up now.

Anyway, whichever side you are on, this is an interesting debate…

If only we were disinterested spectators…